On 15 April, researchers from the Innovative Medicines Initiative-funded MOPEAD project published a paper on the identification of undiagnosed dementia cases using a web‐based pre‐screening tool in the journal Alzheimer's & Dementia. The overall aim of the MOPEAD study was to assess different Patient Engagement models across Europe, to identify efficient approaches of earlier identification of mild Alzheimer's disease (AD) dementia and prodromal AD patients.
As part of this, project collaborators developed a marketing campaign and a web‐based pre‐screening tool. Participants who showed signs of possible cognitive impairment were invited to memory clinics for a harmonized clinical evaluation across all study sites.
The team reported that 1.487 individuals completed the pre‐screening, out of which 547 were identified to be at risk of dementia. Furthermore, the researchers report that among the subset of 91 participants who received a positive pre‐screening and underwent the full clinical evaluation at one of the memory clinics, 49 (53.8%) were diagnosed with either mild cognitive impairment or AD. The paper therefore concludes that the web‐based pre‐screening tool showed to be a valid strategy to identify so far undiagnosed people who have with cognitive impairment. Read the full paper here:
